Biopharmaceutical production is surging rapidly at the bio cluster in Songdo International City, Incheon.
According to the Incheon Free Economic Zone Authority on the 18th, total biopharmaceutical production capacity at the Songdo Bio Cluster is projected to grow from 1.035 million liters last year to 2.14 million liters by 2030. Production capacity in Songdo has increased sharply from 50,000 liters in 2010 to 330,000 liters in 2015 and 560,000 liters in 2020.
The authority forecast that Songdo's biopharmaceutical production capacity will reach 1.155 million liters this year once Lotte Biologics' Plant 1 (120,000 liters) is completed by year-end.
Samsung Biologics currently has 785,000 liters of production capacity and plans to expand to 1.325 million liters by completing its second bio campus (Plants 5-8) by 2032. Lotte Biologics plans to sequentially build Plants 2 and 3, each with 120,000-liter capacity.
Celltrion, which has 250,000 liters of capacity, is constructing a new drug product (DP) plant targeted for completion this year and will begin full-scale production next year.
The Bio Process Training Center at Yonsei University's Songdo International Campus, which opened late last year, trains approximately 2,000 bio specialists annually.
"We will develop Incheon into a world-class mega bio cluster based on our production capabilities and specialized bio workforce," said Hong Jun-ho, Deputy Commissioner of the Incheon Free Economic Zone Authority (acting commissioner).